Skip to main content
Equibles
ATXI logo

ATXI · Avenue Therapeutics, Inc. · Metrics

Track ATXI — free

Use ATXI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ATXI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.38 -0.05 (-10.71%) At close · Mar 19
Rebalance outlook locked
Going-concern doubt — flagged Aug 7, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors individually and collectively cause substantial doubt about the Company's ability to continue as a going concern to exist within one year from the date of this report.”
View the 10-Q filed Aug 7, 2026
Market Cap
$848,783
Shares
3.29M

ATXI metrics

36 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.38
Market cap
$848,783

Price action

20 metrics
Price change (1W)
-60.3%
Price change (30D)
—
Price change (3M)
-79.6%
Price change (6M)
-86.1%
Price change (YTD)
-81.3%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
98.6%
Annualized volatility (3M)
—
Beta
—
RSI (14D)
17.1
Price vs SMA 50
-72.1%
Price vs SMA 200
-83.5%
Avg volume (3M)
426,696
Relative volume
0.4
Average dollar volume
$738,078

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.29M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.5
reciprocal yield 67.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-327.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-219.6%
Trailing 12 months
Net margin
-207.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$2.90M
Net income (TTM)
−$2.78M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.58

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
-306.0%
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+459.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-488.0%
Return on assets
-140.5%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
7.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.94M
Total assets
$1.98M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.38M
Capital expenditures (TTM)
—
R&D (TTM)
$881,000
SG&A (TTM)
—
Stock compensation (TTM)
$427,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1644963 CUSIP 05360L403 Visit website Investor relations